346 related articles for article (PubMed ID: 1997108)
21. Thyroiditis after treatment with interleukin-2 and interferon alpha-2a.
Pichert G; Jost LM; Zöbeli L; Odermatt B; Pedia G; Stahel RA
Br J Cancer; 1990 Jul; 62(1):100-4. PubMed ID: 2390468
[TBL] [Abstract][Full Text] [Related]
22. Short-duration in vitro interleukin-2-activated mononuclear cells for advanced cancer. A Hong Kong biotherapy pilot study trial.
Yeung AW; Pang YK; Tsang YC; Wong SW; Leung JS
Cancer; 1993 Jun; 71(11):3633-9. PubMed ID: 8387882
[TBL] [Abstract][Full Text] [Related]
23. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
[TBL] [Abstract][Full Text] [Related]
24. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
26. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.
Law TM; Motzer RJ; Mazumdar M; Sell KW; Walther PJ; O'Connell M; Khan A; Vlamis V; Vogelzang NJ; Bajorin DF
Cancer; 1995 Sep; 76(5):824-32. PubMed ID: 8625186
[TBL] [Abstract][Full Text] [Related]
27. Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.
Sosman JA; Hank JA; Moore KH; Borchert A; Schell K; Kohler PC; Goldstein D; Bechhofer R; Storer B; Albertini MR
Cancer Invest; 1991; 9(1):35-48. PubMed ID: 2012995
[TBL] [Abstract][Full Text] [Related]
28. Low-dose intravenous bolus interleukin-2 with interferon-alpha therapy for metastatic melanoma and renal cell carcinoma.
Karp SE
J Immunother; 1998 Jan; 21(1):56-61. PubMed ID: 9456437
[TBL] [Abstract][Full Text] [Related]
29. Intensive regimen of cytokines with interleukin-2 and interferon alfa-2b in selected patients with metastatic renal carcinoma.
Négrier S; Mercatello A; Bret M; Merrouche Y; Coronel B; Favrot M; Gaspard M; Dorez D; Philip I; Lanier F
J Immunother Emphasis Tumor Immunol; 1995 Jan; 17(1):62-8. PubMed ID: 7728307
[TBL] [Abstract][Full Text] [Related]
30. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
32. A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population.
Clark JI; Kuzel TM; Lestingi TM; Fisher SG; Sorokin P; Martone B; Viola M; Sosman JA
Ann Oncol; 2002 Apr; 13(4):606-13. PubMed ID: 12056712
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFN alpha) in metastatic melanoma.
Kruit WH; Goey SH; Monson JR; Stahel RA; Calabresi F; Mertelsmann R; Holdener EE; Eggermont AM; Bolhuis RL; de Mulder PH
Br J Haematol; 1991 Oct; 79 Suppl 1():84-6. PubMed ID: 1931717
[TBL] [Abstract][Full Text] [Related]
34. Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN.
Wersäll P; Mellstedt H
Med Oncol; 1995 Jun; 12(2):69-77. PubMed ID: 8535664
[TBL] [Abstract][Full Text] [Related]
35. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
[TBL] [Abstract][Full Text] [Related]
36. [Combination therapy with recombinant interferon alpha-21 (rIFN alpha 2a) and recombinant interleukin 2 (rIL-2) in metastatic renal cell cancer].
Jurincic-Winkler C; Horlbeck R; Klippel KF
Wien Klin Wochenschr; 1993; 105(10):271-6. PubMed ID: 8517056
[TBL] [Abstract][Full Text] [Related]
37. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
38. A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma.
Amato RJ; Shetty A; Lu Y; Ellis PR; Mohlere V; Carnahan N; Low PS
J Immunother; 2014 May; 37(4):237-44. PubMed ID: 24714357
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.
Gaynor ER; Weiss GR; Margolin KA; Aronson FR; Sznol M; Demchak P; Grima KM; Fisher RI; Boldt DH; Doroshow JH
J Natl Cancer Inst; 1990 Sep; 82(17):1397-402. PubMed ID: 2388289
[TBL] [Abstract][Full Text] [Related]
40. A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients.
Deprés-Brummer P; Levi F; Di Palma M; Beliard A; Lebon P; Marion S; Jasmin C; Misset JL
J Immunother (1991); 1991 Dec; 10(6):440-7. PubMed ID: 1768678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]